This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
by Zacks Equity Research
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
What Makes Glaukos (GKOS) a New Buy Stock
by Zacks Equity Research
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 33.33% and 3.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
by Zacks Equity Research
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
by Zacks Equity Research
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Earnings Preview: Mettler-Toledo (MTD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
by Zacks Equity Research
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
by Zacks Equity Research
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
by Urmimala Biswas
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
by Zacks Equity Research
Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.